Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1992807 | 0.88 | L3MBTL1 (0.49) | L3MBTL1HTR6PTGDR2KDM4EEPHX1 | |
| SCHEMBL28935614 | 0.85 | L3MBTL1 (0.46) | L3MBTL1HTR6PTGDR2EPHX1FEN1 | |
| SCHEMBL28935624 | 0.85 | PTGDR2 (0.48) | L3MBTL1HTR6PTGDR2EPHX1FEN1 | |
| SCHEMBL1993957 | 0.84 | L3MBTL1 (0.44) | L3MBTL1HSD17B10TSHRPTGDR2KDM4E | |
| SCHEMBL28935653 | 0.82 | L3MBTL1 (0.43) | L3MBTL1HTR6PTGDR2EPHX1FEN1 | |
| SCHEMBL1998282 | 0.81 | L3MBTL1 (0.65) | L3MBTL1HTR6HSD17B10TSHRPTGDR2 | |
| SCHEMBL28935720 | 0.80 | L3MBTL1 (0.57) | L3MBTL1HTR6KDM4ESMN1; SMN2 | |
| SCHEMBL1988689 | 0.80 | L3MBTL1 (0.46) | L3MBTL1HTR6HSD17B10TSHRKDM4E | |
| SCHEMBL28935605 | 0.80 | L3MBTL1 (0.43) | L3MBTL1HTR6PTGDR2EPHX1FEN1 | |
| SCHEMBL5740608 | 0.79 | L3MBTL1 (1.00) | L3MBTL1HTR6KDM4EEPHX1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115611895-A | Arylamino derivative estrogen receptor modulators and uses thereof | 四川海思科制药有限公司 | 2023-01-17 | — | — | CN | disclosed |
| WO-2011079105-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011079105-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | WO | disclosed |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | TPMT, TSLP, THPO | L3MBTL1 3898/4885HTR6 368/4885HSD17B10 2995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.